I primi 10 basser.org competitors

facingourrisk.org

Learn how gene mutations can lead to cancer, what types of cancer may be hereditary and how parents can pass inherited mutations to their children.

grayfoundation.org

The Gray Foundation has a dual mission.  We accelerate research, raise awareness, and improve treatment for individuals and families with inherited BRCA mutations and related cancers.  We expand access to education, healthcare and opportunity for New York City Youth from low-income backgrounds. © 2025 Gray Foundation.

prevention.cancer.gov

Cancer prevention, including early detection, is essential to reducing the public health burden of cancer in the United States. The CPFP was created in 1987 to

mirakind.org

Staying on top of health-related knowledge can be overwhelming. With constant advancements in science, it’s not always easy to keep track of new findings. Yet, it’s important to know which discoveries are beneficial to our health and which ones identify potential risks. In a previous post, we discussed several risk factors associated with breast cancer, …

golublab.broadinstitute.org

Background: We aimed to examine circulating tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive assay in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy. Patients and methods: We identified responders (RCB 0/1) and matched non-responders (RCB 2/3) from the phase II TBCRC 030 prospective study of neoadjuvant paclitaxel versus cisplatin in TNBC. We collected plasma samples at baseline, 3 weeks and 12 weeks (end of therapy). We created personalized ctDNA assays utilizing MAESTRO mutation enrichment sequencing. We explored associations between ctDNA and RCB status and disease recurrence. Results: Of 139 patients, 68 had complete samples and no additional neoadjuvant chemotherapy. Twenty-two were responders and 19 of those had sufficient tissue for whole-genome sequencing. We identified an additional 19 non-responders for a matched case-control analysis of 38 patients using a MAESTRO ctDNA assay tracking 319-1000 variants (median 1000 variants) to 114 plasma samples from 3 timepoints. Overall, ctDNA positivity was 100% at baseline, 79% at week 3 and 55% at week 12. Median tumor fraction (TFx) was 3.7 × 10-4 (range 7.9 × 10-7-4.9 × 10-1). TFx decreased 285-fold from baseline to week 3 in responders and 24-fold in non-responders. Week 12 ctDNA clearance correlated with RCB: clearance was observed in 10 of 11 patients with RCB 0, 3 of 8 with RCB 1, 4 of 15 with RCB 2 and 0 of 4 with RCB 3. Among six patients with known recurrence, five had persistent ctDNA at week 12. Conclusions: Neoadjuvant chemotherapy for TNBC reduced ctDNA TFx by 285-fold in responders and 24-fold in non-responders. In 58% (22/38) of patients, ctDNA TFx dropped below the detection level of a commercially available test, emphasizing the need for sensitive tests. Additional studies will determine whether ctDNA-guided approaches can improve outcomes.

liferaftgroup.org

Newly Diagnosed  |  Glossary  |  GIST Education  |  GIST FAQs  |  Pathology Report Less than 20 years ago, GIST was a disease frequently misdiagnosed – usually as leiomyosarcoma . Today, we

curestarterprizedraw.org

Win great prizes and start lifesaving cancer cures

lustgarten.org

The Koch Institute unites biologists, chemists, engineers, computer scientists, and clinicians for an interdisciplinary approach to the fight against cancer.

glioblastomafoundation.org

Rock Against Glioblastoma is a music festival to benefit Glioblastoma Foundation and fund research for new treatments for Glioblastoma

igcs.org

At IGCS, member engagement and volunteerism connect our global community in meaningful ways. No matter where you live, you can help improve care for women with gynecologic cancers and support our mission at the level that’s right for you. Get Involved! How You Can Get InvolvedMentorship & Knowledge Sharing Mentor trainees in low-resource settings through IGCS programs. Share expertise and strengthen global care teams. Education & Training Lead or contribute to webinars, podcasts, and tumor boards. Help advance multidisciplinary learning worldwide. Research & Scholarship Review manuscripts for the International Journal of Gynecological Cancer (IJGC). Join collaborative studies and rare tumor registries. Events & Community Engagement Get involved in IGCS’s Annual Global Meeting as a reviewer, planner, or faculty member. Connect with our global community through regional and Special Interest Networks Lend Your Voice to IGCSClick the button to complete a brief interest form to let us know how you’d like to get involved. Start Connecting NowLearn more about Regional Connect Virtual GatheringsLearn more about IGCS Special Interest Networks